From inflammation to prostate cancer: The role of inflammasomes

Advances in Urology

Volumn 2016, Issue , 2016, Pages

  Karan, Dev ^a   Dubey, Seema ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84982845403     PISSN: 16876369     EISSN: 16876377     Source Type: Journal    
DOI: 10.1155/2016/3140372     Document Type: Review

References (61)

1. R. L. Siegel, K. D. Miller, and A. Jemal, "Cancer statistics, 2016," CA-A Cancer Journal for Clinicians, vol. 66, no. 1, pp. 7-30, 2016.
2. D. Karan, J. B. Trasher, and D. Lubarof, "Prostate cancer: genes, environment, immunity and the use of immunotherapy," Prostate Cancer and Prostatic Diseases, vol. 11, no. 3, pp. 230-236, 2008.
3. F. Martinon and J. Tschopp, "Infammatory caspases and infammasomes: master switches of infammation," Cell Death and Diferentiation, vol. 14, no. 1, pp. 10-22, 2007.
4. B. K. Davis, H. Wen, and J. P.-Y. Ting, "The Infammasome NLRs in immunity, infammation, and associated diseases," Annual Review of Immunology, vol. 29, pp. 707-735, 2011.
5. R. J. Cohen, B. A. Shannon, M. Phillips, R. E. Moorin, T. M. Wheeler, and K. L. Garrett, "Central zone carcinoma of the prostate gland: a distinct tumor type with poor prognostic features," The Journal of Urology, vol. 179, no. 5, pp. 1762-1767, 2008.
6. A. M. De Marzo, E. A. Platz, S. Sutclife et al., "Infammation in prostate carcinogenesis," Nature Reviews Cancer, vol. 7, no. 4, pp. 256-269, 2007.
7. A. Sciarra, G. Mariotti, S. Salciccia et al., "Prostate growth and infammation," Journal of Steroid Biochemistry and Molecular Biology, vol. 108, no. 3-5, pp. 254-260, 2008.
8. S. Vasto, G. Carruba, G. Candore, E. Italiano, D. Di Bona, and C. Caruso, "Infammation and prostate cancer," Future Oncology, vol. 4, no. 5, pp. 637-645, 2008.
9. L. M. Coussens and Z. Werb, "Infammation and cancer," Nature, vol. 420, no. 6917, pp. 860-867, 2002.
10. W. G. Nelson, A. M. De Marzo, T. L. DeWeese et al., "The role of infammation in the pathogenesis of prostate cancer," Journal of Urology, vol. 172, no. 5, pp. S6-S12, 2004.
11. H. Kuper, H.-O. Adami, and D. Trichopoulos, "Infections as a major preventable cause of human cancer," Journal of Internal Medicine, vol. 248, no. 3, pp. 171-183, 2000.
12. D. G. DeNardo, M. Johansson, and L. M. Coussens, "Immune cells as mediators of solid tumor metastasis," Cancer and Metastasis Reviews, vol. 27, no. 1, pp. 11-18, 2008.
13. J. B. Swann, M. D. Vesely, A. Silva et al., "Demonstration of infammation-induced cancer and cancer immunoediting during primary tumorigenesis," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 2, pp. 652-656, 2008.
14. D. Hanahan and R. A. Weinberg, "Hallmarks of cancer: the next generation," Cell, vol. 144, no. 5, pp. 646-674, 2011.
15. D. M. Moreira, D. G. Bostwick, G. L. Andriole et al., "Baseline prostate atrophy is associated with reduced risk of prostate cancer in men undergoing repeat prostate biopsy," The Journal of Urology, vol. 194, no. 5, pp. 1241-1246, 2015.
16. D. M. Moreira, J. C. Nickel, G. L. Andriole, R. Castro-Santamaria, and S. J. Freedland, "Chronic baseline prostate infammation is associated with lower tumor volume in men with prostate cancer on repeat biopsy: results from the REDUCE study," The Prostate, vol. 75, no. 13, pp. 1492-1498, 2015.
17. T. H. Yli-Hemminki, M. Laurila, A. Auvinen et al., "Histological infammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specifc antigen (PSA) concentration in the Finnish prostate cancer screening trial," BJU International, vol. 112, no. 6, pp. 735-741, 2013.
18. B. H. Yun, E. C. Hwang, H. S. Yu et al., "Is histological prostate infammation in an initial prostate biopsy a predictor of prostate cancer on repeat biopsy?" International Urology and Nephrology, vol. 47, no. 8, pp. 1251-1257, 2015.
19. W. Zhang, I. A. Sesterhenn, R. R. Connelly, F. K. Mostof, and J. W. Moul, "Infammatory infltrate (prostatitis) in whole mounted radical prostatectomy specimens from black and white patients is not an etiology for racial diference in prostate specifc antigen," The Journal of Urology, vol. 163, no. 1, pp. 131- 136, 2000.
20. B. A. Rybicki, O. N. Kryvenko, Y. Wang et al., "Racial diferences in the relationship between clinical prostatitis, presence of infammation in benign prostate and subsequent risk of prostate cancer," Prostate Cancer and Prostatic Diseases, vol. 19, pp. 145- 150, 2016.
21. B. Gurel, M. S. Lucia, I. M. Tompson Jr. et al., "Chronic infammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial," Cancer Epidemiology Biomarkers and Prevention, vol. 23, no. 5, pp. 847-856, 2014.
22. A. Strasner and M. Karin, "Immune infltration and prostate cancer," Frontiers in Oncology, vol. 5, article 128, 2015.
23. A. Vral, V. Magri, E. Montanari et al., "Topographic and quantitative relationship between prostate infammation, proliferative infammatory atrophy and low-grade prostate intraepithelial neoplasia: a biopsy study in chronic prostatitis patients," International Journal of Oncology, vol. 41, no. 6, pp. 1950-1958, 2012.
24. A. Celma, P. Servián, J. Planas et al., "Clinical signifcance of proliferative infammatory atrophy in prostate biopsy," Actas Urologicas Espanolas, vol. 38, no. 2, pp. 122-126, 2014.
25. K. Fujita, M. Hosomi, G. Tanigawa, M. Okumi, H. Fushimi, and S. Yamaguchi, "Prostatic infammation detected in initial biopsy specimens and urinary Pyuria are predictors of negative repeat prostate biopsy," The Journal of Urology, vol. 185, no. 5, pp. 1722- 1727, 2011.
26. D. P. Nguyen, J. Li, S. S. Yadav, and A. K. Tewari, "Recent insights into NF-κB signalling pathways and the link between infammation and prostate cancer," BJU International, vol. 114, no. 2, pp. 168-176, 2014.
27. B. Hoesel and J. A. Schmid, "The complexity of NF-κB signaling in infammation and cancer," Molecular Cancer, vol. 12, no. 1, article 86, 2013.
28. N. Salazar, M. Castellan, S. S. Shirodkar, and B. L. Lokesh-war, "Chemokines and chemokine receptors as promoters of prostate cancer growth and progression," Critical Reviews in Eukaryotic Gene Expression, vol. 23, no. 1, pp. 77-91, 2013.
29. D. J. J. Waugh, C. Wilson, A. Seaton, and P. J. Maxwell, "Multi-faceted roles for CXC-chemokines in prostate cancer progression," Frontiers in Bioscience, vol. 13, no. 12, pp. 4595- 4604, 2008.
30. I. Heidegger, J. Höfer, M. Luger et al., "Is Eotaxin-1 a serum and urinary biomarker for prostate cancer detection and recurrence?" The Prostate, vol. 75, no. 16, pp. 1904-1909, 2015.
31. E. B. Holliday, N. F. Dieckmann, T. L. McDonald, A. Y. Hung, C. R. Tomas Jr., and L. J. Wood, "Relationship between fatigue, sleep quality and infammatory cytokines during external beam radiation therapy for prostate cancer: a prospective study," Radiotherapy and Oncology: Journal of the European Society for Terapeutic Radiology and Oncology, vol. 118, no. 1, pp. 105-111, 2016.
32. S. Dwivedi, A. Goel, S. M. Natu, A. Mandhani, S. Khattri, and K. K. Pant, "Diagnostic and prognostic signifcance of prostate specifc antigen and serum interleukin 18 and 10 in patients with locally advanced prostate cancer: A Prospective Study," Asian Pacifc Journal of Cancer Prevention, vol. 12, no. 7, pp. 1843-1848, 2011.
33. K. Fujita, C. M. Ewing, W. B. Isaacs, and C. P. Pavlovich, "Immunomodulatory IL-18 binding protein is produced by prostate cancer cells and its levels in urine and serum correlate with tumor status," International Journal of Cancer, vol. 129, no. 2, pp. 424-432, 2011.
34. A. R. Bauskin, D. A. Brown, T. Kufner et al., "Role of macrophage inhibitory cytokine-1β in tumorigenesis and diagnosis of cancer," Cancer Research, vol. 66, no. 10, pp. 4983-4986, 2006.
35. K. S. Selander, D. A. Brown, G. B. Sequeiros et al., "Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases," Cancer Epidemiology Biomarkers & Prevention, vol. 16, no. 3, pp. 532- 537, 2007.
36. S. Tu, G. Bhagat, G. Cui et al., "Overexpression of interleukin-1β induces gastric infammation and cancer and mobilizes myeloid-derived suppressor cells in mice," Cancer Cell, vol. 14, no. 5, pp. 408-419, 2008.
37. M. Terme, E. Ullrich, L. Aymeric et al., "IL-18 induces PD-1-dependent immunosuppression in cancer," Cancer Research, vol. 71, no. 16, pp. 5393-5399, 2011.
38. K. Schroder and J. Tschopp, "The Infammasomes," Cell, vol. 140, no. 6, pp. 821-832, 2010.
39. G. Y. Chen and G. Núñez, "Infammasomes in intestinal infammation and cancer," Gastroenterology, vol. 141, no. 6, pp. 1986-1999, 2011.
40. M. Fabbi, G. Carbotti, and S. Ferrini, "Context-dependent role of IL-18 in cancer biology and counter-regulation by IL-18BP," Journal of Leukocyte Biology, vol. 97, no. 4, pp. 665-675, 2015.
41. D. A. C. Deans, S. J. Wigmore, H. Gilmour, S. Paterson-Brown, J. A. Ross, and K. C. H. Fearon, "Elevated tumour interleukin-1β is associated with systemic infammation: a marker of reduced survival in gastro-oesophageal cancer," British Journal of Cancer, vol. 95, no. 11, pp. 1568-1575, 2006.
42. C. A. Dinarello, "Immunological and infammatory functions of the interleukin-1 family," Annual Review of Immunology, vol. 27, pp. 519-550, 2009.
43. M. Okamoto, W. Liu, Y. Luo et al., "Constitutively active infam-masome in human melanoma cells mediating autoinfamma-tion via caspase-1 processing and secretion of interleukin-1β," The Journal of Biological Chemistry, vol. 285, no. 9, pp. 6477- 6488, 2010.
44. C. Dostert, G. Guarda, J. F. Romero et al., "Malarial hemozoin is a Nalp3 infammasome activating danger signal," PLoS ONE, vol. 4, no. 8, Article ID e6510, 2009.
45. V. Hornung, F. Bauernfeind, A. Halle et al., "Silica crystals and aluminum salts activate the NALP3 infammasome through phagosomal destabilization," Nature Immunology, vol. 9, no. 8, pp. 847-856, 2008.
46. C.-S. Chen, P.-J. Chang, W.-Y. Lin, Y.-C. Huang, and D.-R. Ho, "Evidences of the infammasome pathway in chronic prostatitis and chronic pelvic pain syndrome in an animal model," The Prostate, vol. 73, no. 4, pp. 391-397, 2013.
47. M. Kashyap, S. Pore, Z. Wang, J. Gingrich, N. Yoshimura, and P. Tyagi, "Infammasomes are important mediators of prostatic infammation associated with BPH," Journal of Infammation, vol. 12, article 37, 2015.
48. L. Ponomareva, H. Liu, X. Duan et al., "AIM2, an IFN-inducible cytosolic DNA sensor, in the development of benign prostate hyperplasia and prostate cancer," Molecular Cancer Research, vol. 11, no. 10, pp. 1193-1202, 2013.
49. Q. Liu, M. R. Russell, K. Shahriari et al., "Interleukin-1β promotes skeletal colonization and progression of metastatic prostate cancer cells with neuroendocrine features," Cancer Research, vol. 73, no. 11, pp. 3297-3305, 2013.
50. J. Schulze, K. Weber, A. Baranowsky et al., "P65-Dependent production of interleukin-1β by osteolytic prostate cancer cells causes an induction of chemokine expression in osteoblasts," Cancer Letters, vol. 317, no. 1, pp. 106-113, 2012.
51. C. A. Dinarello, A. Simon, and J. W. M. Van Der Meer, "Treating infammation by blocking interleukin-1 in a broad spectrum of diseases," Nature Reviews Drug Discovery, vol. 11, no. 8, pp. 633-652, 2012.
52. D. S. Hong, D. Hui, E. Bruera et al., "MABp1, a frst-in-class true human antibody targeting interleukin-1β in refractory cancers: An open-label, phase 1 dose-escalation and expansion study," The Lancet Oncology, vol. 15, no. 6, pp. 656-666, 2014.
53. "A phase 3 study to evaluate Xilonix as an anticancer therapy in patients with symptomatic colorectal cancer," https://clinicaltrials.gov/ct2/show/NCT02138422.
54. M. T. Chow, J. Sceneay, C. Paget et al., "NLRP3 suppresses NK cell-mediated responses to carcinogen-induced tumors and metastases," Cancer Research, vol. 72, no. 22, pp. 5721-5732, 2012.
55. F. Knauf, J. R. Asplin, I. Granja et al., "NALP3-mediated infammation is a principal cause of progressive renal failure in oxalate nephropathy," Kidney International, vol. 84, no. 5, pp. 895-901, 2013.
56. I. C. Allen, E. M. Tekippe, R.-M. T. Woodford et al., "Te NLRP3 infammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer," Te Journal of Experimental Medicine, vol. 207, no. 5, pp. 1045-1056, 2010.
57. R. Kolb, G.-H. Liu, A. M. Janowski, F. S. Sutterwala, and W. Zhang, "Infammasomes in cancer: a double-edged sword," Protein and Cell, vol. 5, no. 1, pp. 12-20, 2014.
58. M. Terlizzi, V. Casolaro, A. Pinto, and R. Sorrentino, "Infamma-some: cancer's friend or foe?" Pharmacology and Terapeutics, vol. 143, no. 1, pp. 24-33, 2014.
59. S. K. Drexler and A. S. Yazdi, "Complex roles of infammasomes in carcinogenesis," Cancer Journal, vol. 19, no. 6, pp. 468-472, 2013.
60. H. Guo, J. B. Callaway, and J. P.-Y. Ting, "Infammasomes: mechanism of action, role in disease, and therapeutics," Nature Medicine, vol. 21, no. 7, pp. 677-687, 2015.
61. L. Zitvogel, O. Kepp, L. Galluzzi, and G. Kroemer, "Infam-masomes in carcinogenesis and anticancer immune responses," Nature Immunology, vol. 13, no. 4, pp. 343-351, 2012.